Financials in USD. Standardized financial statements.
A compact view of how Core Scientific, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $319.02M | $510.67M | $502.40M | $640.31M | $544.48M | $60.32M | $59.52M |
| Revenue Growth? | -37.5% | +1.6% | -21.5% | +17.6% | +802.7% | +1.3% | 0.0% |
| Cost of Revenue? | $281.12M | $389.60M | $378.94M | $631.91M | $305.62M | $50.93M | $49.00M |
| Gross Profit? | $37.90M | $121.07M | $123.46M | $8.40M | $238.86M | $9.39M | $10.53M |
| Gross Margin? | +11.9% | +23.7% | +24.6% | +1.3% | +43.9% | +15.6% | +17.7% |
| Operating Expenses? | $262.45M | $140.27M | $114.50M | $2.12B | $72.22M | $15.72M | $23.02M |
| Operating Income? | -$224.55M | -$19.20M | $8.96M | -$2.11B | $166.64M | -$6.33M | -$11.69M |
| EBITDA? | -$144.37M | -$1.16B | -$63.12M | -$1.84B | $140.79M | $1.63M | -$5.57M |
| Income Before Tax | -$288.03M | -$1.31B | -$245.80M | -$2.16B | $63.08M | -$12.21M | -$11.92M |
| Income Tax Expense | $583,000 | $859,000 | $683,000 | -$17.09M | $15.76M | $0 | $0 |
| Net Income? | -$288.62M | -$1.32B | -$246.49M | -$2.15B | $47.31M | -$12.21M | -$11.92M |
| EPS? | $-0.88 | $-5.14 | $-0.65 | $-6.30 | $0.23 | $-0.06 | $-0.28 |
| Diluted EPS? | $-0.88 | $-5.14 | $-0.65 | $-6.30 | $0.20 | $-0.06 | $-0.28 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality